ACMSD mediated de novo NAD+ biosynthetic impairment in cardiac endothelial cells as a potential therapeutic target for diabetic cardiomyopathy.
Zeng F, Zhou P, Wang M, Xie L, Huang X, Wang Y, Huang J, Shao X, Yang Y, Liu W, Gu M, Yu Y, Sun F, He M, Li Y, Zhang Z, Gong W, Wang Y.
Zeng F, et al. Among authors: gong w.
Diabetes Res Clin Pract. 2023 Dec;206:111014. doi: 10.1016/j.diabres.2023.111014. Epub 2023 Nov 15.
Diabetes Res Clin Pract. 2023.
PMID: 37977551